西妥昔单抗联合FOLFOX化疗治疗转移性结直肠-中国现代应用药学.PDF

西妥昔单抗联合 FOLFOX 化疗治疗转移性结直肠癌的临床研究 刘护民 1 2 ，严熙军 (1.新疆生产建设兵团医院普外科，乌鲁木齐 830002 ；2.新疆医科大学第五附属医院外科，乌鲁木齐 830011) 摘要：目的 观察西妥昔单抗联合 FOLFOX 化疗治疗转移性结直肠癌(MCRC)的近期疗效及不良反应。方法 48 例确诊 为 MCRC 患者为研究对象。西妥昔单抗每周给药，首剂负荷量为 400 mg·m2 ，维持量为 250 mg·m2 ；联合方案：奥沙利 铂 85 mg·m2+5- 氟尿嘧啶 600 mg·m2+亚叶酸钙 200 mg·m2 ，2 周为一个周期。完成两个周期的化疗以后，评价疗效，观 察中位至疾病进展时间和不良反应。结果 完全缓解 0 例，部分缓解 39 例，疾病稳定 9 例，疾病进展 0 例，总有效率 81.3%，疾病控制率 100.0%，中位至疾病进展时间是 9 个月。不良反应主要为 Ⅰ~ Ⅱ级。结论 西妥昔单抗联合 FOLFOX 的化疗方案治疗 MCRC 可获得较高有效率，延长了疾病进展时间，改善了患者的生活质量，值得临床推广应用。 关键词：西妥昔单抗；FOLFOX ；转移性结直肠癌 中图分类号：R969.4 文献标志码：A 文章编号：1007-7693(2010)13-1239-03 Clinical Research of Cetuximab Combined with FOLFOX Chemotherapy for Treating Metastatic Colorectal Cancer 1 2 LIU Humin , YAN Xijun (1.Xinjiang Production and Construction Corps Hospital, Urumqi 830002, China; 2.The Fifth Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China) ABSTRACT: OBJECTIVE To observe the recent efficacy and toxicity of cetuximab combined FOLFOX chemotherapy for treating metastatic colorectal cancer (MCRC). METHODS Forty-eight cases of patients with MCRC were studied. Cetuximab was administered weekly, the first loading dose was 400 mg·m2, maintenance dose was 250 mg·m2 . Joint programme: oxaliplatin 85 mg·m2+5-fluorouracil 600 mg·m2+leucovorin 200 mg·m2, 2 weeks as a cycle. After 2 cycles of chemotherapy, recent efficacy was evaluated, the TTP and toxicity were observed. RESULTS CR 0 case, PR 39 cases, SD 9 cases, PD 0 case, the total effective rate was 81.3%, the disease control rate was 100.0%, the TTP was 9 months. The toxicity was mainly ⅠⅡ grade. CONCLUSION Cetuximab combined with FOLFOX chemotherapy for treating MCRC can get higher efficiency, longer TTP and can improve the quality of patient’s life. It